"Muu" projekt MARMP11049
MARMP11049 "ESTOFINN projekt (1.03.2011−31.12.2011)", Pärt Peterson, Tartu Ülikool, Tartu Ülikool, Arstiteaduskond.
MARMP11049
ESTOFINN projekt
Cloning of antibodies from APECED patients
1.03.2011
31.12.2011
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.7. Kliiniline meditsiinB500 Immunoloogia, seroloogia, transplantoloogia3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)100,0
AsutusRollPeriood
Tartu Ülikoolpartner01.03.2011−31.12.2011
Tartu Ülikool, Arstiteaduskondpartner01.03.2011−31.12.2011
AsutusRiikTüüp
Qube GmbH
PerioodSumma
01.03.2011−31.12.201187 500,00 EUR
87 500,00 EUR
Tartu Ülikooli ja ettevõtte vaheline leping

This project is carried out by research consortium that aims to analyze and to generate human monoclonal antibodies to human cytokines. The consortium partners are two SMEs Qube and CT-Atlantic, and the University of Helsinki and the University of Tartu. The objective of the research agreement is to establish a proof of concept for the cloning of human antibodies against targets of interest. The tasks of Pärt Peterson group include the development of robust immunodetection methods, which are based on fiuorescence detection and ELISA, and their technological transfer to the company named CT-Atlantic, Zurich. Secondly, the Peterson group will test the seronegativity of 20-30 candidate antigens decided jointly with other partners of the consortium. Thirdly, the group will develop functional in vitro test for the monoclonal antibodies generated by CT-Atlantic, Zurich. The research agreement will initially last for one year.
This project is carried out by research consortium that aims to analyze and to generate human monoclonal antibodies to human cytokines. The consortium partners are two SMEs Qube and CT-Atlantic, and the University of Helsinki and the University of Tartu. The objective of the research agreement is to establish a proof of concept for the cloning of human antibodies against targets of interest. The tasks of Pärt Peterson group include the development of robust immunodetection methods, which are based on fiuorescence detection and ELISA, and their technological transfer to the company named CT-Atlantic, Zurich. Secondly, the Peterson group will test the seronegativity of 20-30 candidate antigens decided jointly with other partners of the consortium. Thirdly, the group will develop functional in vitro test for the monoclonal antibodies generated by CT-Atlantic, Zurich. The research agreement will initially last for one year.
TegevusProtsent
Katse- ja arendustöö100,0